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ANTICANCER EFFICACY OF ALLOGENEIC VACCINE MODIFIED 
WITH PROGENITOR NEURAL CELLS SUPERNATANT IN RATS 
WITH GLIOMA 101.8
L.D. Liubich*, M.I. Lisyany
SI “A.P. Romodanov Institute of Neurosurgery of the NAMS of Ukraine”, Kyiv 04050, Ukraine
The aim of the work was to investigate the antitumor efficacy of allogeneic tumor vaccine (ATV) modified with rat progenitor 
neural cell supernatant (RPNS) in rats with glioma 101.8. Materials and Methods: The study was performed on 74 white random-
bred rats. ATV was developed on the basis of glioma 101.8 cell suspension modified with RPNS (0.02 or 0.10 mg/ml). RPNS was 
prepared from suspension made from whole rat brain tissue on 14th (E14) day of gestation. Model of brain glioma 101.8 was re-
produced by intracerebral injection of glioma 101.8 cell suspension. ATV was injected intraperitoneally in a volume of 0.2 ml per 
animal once on the 10th day after tumor transplantation. For survival analysis Kaplan — Mayer multiple assessments method was 
used. Cytotoxic activity of rat lymphocytes (effector cells) was evaluated in MTT-colorimetric test by determining the state of mi-
tochondrial dehydrogenase enzymes in target cells (allogeneic glioma 101.8 cells). Results: Intraperitoneal administration of ATV 
modified with 0.10 mg/ml RPNS significantly increased mean survival time and median survival of glioma-bearing rats compared 
with unvaccinated group (MST (19.9 ± 2.4), 21.4 days; versus MST (14.6 ± 2.8); 14 days; p = 0.0002, Gehan’s — Wilcoxon test). 
Intraperitoneal administration of ATV modified with 0.10 mg/ml RPNS resulted in increased cytotoxic activity of immune cells 
of rats with glioma in vitro compared with this index in unvaccinated group (p = 0.026, U-Mann — Whitney test). Conclusion: 
Antitumor effect of vaccination with RPNS-modified ATV is realized via increased cytotoxic activity of immune cells, what could 
be used for further optimization of whole tumor cell vaccine.
Key Words: allogeneic tumor vaccine, rat progenitor neural cells supernatant, glioma 101.8, mean survival time, lymphocyte 
cytotoxic function.
Despite substantial progress in the development 
of modern methods of tumor treatment, the therapy 
of cancer patients, particularly patients with brain 
gliomas remains of low effectiveness.
Gliomas are the most common primary brain tu-
mors, which are characterized by infiltrative growth 
and resistance to therapy. Patients with glioma have 
a poor prognosis. For immune recognition and elimi-
nation of tumor cells realization of a series of steps 
is necessary that are implemented by innate and 
adaptive arms of immune system, but in gliomas, 
especially malignant ones, several mechanisms are 
utilized to avoid the control by the immune system. 
These mechanisms include: 1) reducing the number 
and function of immune cells, along with an increase 
in the number of T-regulatory CD4+CD25+FoxP3+ cells 
producing immunoinhibitory mediators [1–4]; 2) we-
akening of the immune response due to the formation 
of immunosuppressive tumor environment through 
the secretion of prostaglandin E2, IL-10, TGF-β, gan-
gliosides [5]; 3) loss of expression of the classical 
major histocompatibility complex molecules (MHC), 
along with the appearance of expression of nonclas-
sical molecules (HLA-G, -E) with immunomodulating 
properties [6–10].
Development of new approaches that will over-
come mechanisms by which tumor avoid the control 
of the immune system and tumor suppressive effects 
on immunocompetent cells, is an important task. 
Advances in molecular biology of gliomas are quickly 
translated into innovative clinical trials of new methods 
of therapy, based on in-depth genomic, epigenetic, 
transcriptional and proteomic characteristics of tumor 
and factors of brain microenvironment interaction with 
the immune system. Along with the use of radiation, 
cryotherapy, chemotherapy, photodynamic therapy, 
oncolytic viruses etc. among novel approaches there 
are considered: 1) the use of facilities that enhance 
antigen presentation (targeted agents, vaccines, 
agonists of Toll-like receptors, type I interferons); 
2) therapies targeting the growth factor receptors and 
adjoint downstream signaling pathways expressed 
by tumor, angiogenesis, modulation of tumor stem 
cells (TSC), the regulation of the cell cycle; 3) the use 
of agents aimed at reversal T-cell dysfunction (inhibi-
tors of the “immune checkpoints” — an antibody against 
an cytotoxic T-lymphocyte antigen 4 ( CTLA-4) and 
programmed death receptor 1 (PD-1)); 4) the use 
of agents aimed at other immunoinhibitory mecha-
nisms (inhibitors of indolamine-dioxygenase, regula-
tory T cells, myeloid suppressor cells) [11, 12].
Immunotherapy of malignant gliomas using the in-
nate ability of the immune system to recognize and 
destroy malignant cells is considered a promising 
as provides highly specific and less toxic therapy 
compared with conventional chemotherapy [4, 11]. 
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Immunotherapy of tumors includes the following ap-
proaches: the use of dendritic cells, adoptive  T-cell 
therapy, anti-tumor antibodies, tumor vaccines, 
blockade of immune checkpoints [13]. Immuno-
therapy of gliomas is based mainly on active immuni-
zation against tumor antigens, that is an introduction 
of immunogen to generate response in tumor-carrier 
in order to eliminate malignant cells [14]. In recent 
years, new approaches for cancer vaccine genera-
tion are developed, based on the use of whole tumor 
cells or specific antigens (peptide vaccines) which are 
evaluated in clinical trials [15, 16].
Immunotherapy based on whole tumor cells vac-
cines is considered to be perspective [17]. In experi-
mental and clinical studies the effectiveness of tumor 
autovaccine [18] and xenogeneic analogs of endo-
genous molecules has been demonstrated; such im-
munization is capable to overcome immune tolerance 
to tumor antigens and leads to a significant inhibition 
of tumor development [19]. The basis for the new 
biotherapeutic approach — design of the effective 
oncofetal tumor vaccine — is the use of embryonic and 
fetal tissues [20, 21]. Cellular and molecular similari-
ties between TSC of brain tumors and normal neural 
stem cells (NSC) justify the development of treatment 
strategies using NSC and neurogenic progenitor cells 
(NPC) in malignant gliomas [22–24].
The aim of the work was to investigate the antitumor 
efficacy of allogeneic tumor vaccine (ATV) modified 
by rat progenitor neural cells supernatant (RPNS) 
in rats with glioma 101.8.
MATERIALS AND METHODS
The study was performed on white random-bred 
male rats (n = 74, weight 120 ± 10 g bred in the vivarium 
of SI “A.P. Romodanov Institute of Neurosurgery of the 
NAMS of Ukraine” (“INH NAMS”)). The use and care 
of experimental animals have been performed in com-
pliance with law of Ukraine “On protection of animals 
from cruelty”, “European Convention for the protec-
tion of vertebrate animals used for experimental and 
other scientific purposes”, in accordance with the 
principles of bioethics and biosafety regulations and 
were approved by the Committee on Bioethics Control 
of “INH NAMS”. The animals were kept under standard 
vivarium conditions, anesthesia and euthanasia was 
performed under ether narcosis.
Animals were grouped as following: 1) rats with 
glioma 101.8 (n = 38); 2) rats with glioma 101.8 treated 
by administration of ATV modified with RPNS at a con-
centration of 0.02 mg/ml (n = 12); 3) rats with glioma 
101.8 treated by administration of ATV modified with 
RPNS at a concentration of 0.10 mg/ml (n = 12); 4) in-
tact rats (control, n = 12).
The model of brain glioma was reproduced 
by intracerebral injection of 0.02 ml (3.5 • 105) glioma 
101.8 cell suspension (Russian Collection of Cell 
Cultures, Institute of Human Morphology of Russian 
Academy of Sciences, Moscow, Russian Federa-
tion) in the left hemisphere of the rat brain to a depth 
of 1.5–2.0 mm. Strain 101.8 is anaplastic glioma 
in which astrocytes, oligodendrocytes and ependyma 
simultaneously have undergone malignization, and 
its histobiological properties are close to the human 
malignant gliomas [25].
RPNS was prepared from a suspension of neu-
rogenic rat brain cells on 14th (E14) day of gestation. 
Native rat brain tissue was released from envelopes 
in buffered saline, transferred to DMEM medium 
(Sigma, Germany) and suspended by repeated pipet-
ting. Cells were precipitated by centrifugation for 5 min 
at 1500 rpm, washed in DMEM, and resuspended 
in fresh DMEM. The viability of cells in suspension was 
determined in a standard test with 0.2% trypan blue 
(Merck, Germany). The concentration of cells was ad-
justed to 6.0•106/ml, concanavalin A (0.10 mg/ml) was 
added to the resulting cell suspension, and the cells 
were incubated for 2 h in a CO2-incubator at 37.0 °C, 
constant humidity of 95% and 5% CO2. After incubation, 
the cells were precipitated by centrifugation for 5 min 
at 1500 rpm, washed in medium DMEM, resuspended 
in fresh DMEM medium and incubated at the same 
conditions for 24 h. After incubation, the cells were re-
precipitated by centrifugation for 5 min at 1500 rpm, and 
the supernatant was collected. Protein concentration 
in supernatant was determined by the method of Lowry. 
RPNS was standardized to a concentration of 1.0 mg/
ml, and stored in aliquots at −20.0 °C.
ATV was developed on the basis of glioma 101.8 cell 
suspension, modified with RPNS (0.02 or 0.10 mg/ml). 
RPNS (0.02 or 0.10 mg/ml) was added to a suspen-
sion of fresh-isolated tumor cells (2.0•106), and then 
the suspension in the volume of 2 ml was incubated 
in biologically inert glass centrifuge tubes with periodic 
shaking for 24 h in a CO2-incubator at a temperature 
of 37.0 °С, constant humidity of 95% and 5% CO2. 
We have previously shown that incubation with RPNS 
has cytotoxic and antiproliferative effects on glioma 
101.8 cells (cytotoxic index was 68–86%) [26]. After 
incubation, the cells were precipitated by centrifu-
gation for 5 min at 1500 rpm, washed in DMEM and 
resuspended in fresh DMEM.
ATV was injected intraperitoneally in a volume 
of 0.2 ml (2.8•105) per animal once on the 10th day 
after tumor transplantation.
As a source of immune cells (lymphocytes) spleens 
of experimental animals were used and exa mined at the 
peak of clinical manifestations of glioma 101.8 (17th 
day after tumor transplantation). The animals were 
anesthetized, the spleens were removed, splenocyte 
suspension was prepared by mechanical homogeniza-
tion in RPMI medium and filtered through a nylon filter. 
Lymphocytes were isolated by centrifugation in fikoll-
verografin gradient (ρ = 1.077) at 1500 rpm for 30 min, 
then washed twice in buffered saline pH 7.2–7.4. Cell vi-
ability was determined by the permeability of the plasma 
membrane for 0.2% trypan blue (Merck, Germany). The 
obtained cells were examined in MTT-colorimetric test 
by determining the state of mitochondrial dehydroge-
nase enzymes in target cells.
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Study of lymphocyte cytotoxic activity in MTT-colo-
rimetric test was conducted by the protocol [27]. Lym-
phocytes of animals from experimental groups were 
used as effector cells (5•107/ml); glioma 101.8 cells 
were used as target cells (1•107/ml). In previously 
studies using effector-target ratio of 20:1, 10:1, 5:1, 
it was found that the optimal ratio was 5:1, which was 
used in this study. The test was performed in the trip-
lets. Cytotoxic activity of lymphocytes was represented 
by cytotoxic index (CI) expressed in percent:
CІ = 100 – (ОDе+t – ОDе • 100) / ОDt %,
wherе ОD е+t — optical density values in wells with 
effector + target;
ОD е — optical density values in wells with effectors;
ОD t — optical density values in wells with targets.
Statistical analysis of data was performed  using 
the statistical software package “Statistica 6.0” 
(Software StatSoft Inc., 2003). For survival analysis 
Kaplan — Mayer multiple assessments method with 
Gehan’s — Wilcoxon criteria was used, which allows 
to assess animal survival, regardless of whether it is full 
or censored sampling. For statistical analysis of cyto-
toxic activity indexes ANOVA by Ranks Kruskal — Wallis 
test was used for comparison of multiple indepen-
dent groups, and U-Mann — Whitney test for paired 
comparison of groups. Data are presented as M ± m 
(mean ± SE). p < 0.05 was considered as statistically 
significant difference, p < 0.01 as highly statistically 
significant difference.
RESULTS AND DISCUSSION
The effectiveness of the administration of RPNS-
modified ATV in experimental animals with glioma 
101.8 was determined using survival analysis. Ap-
plication of Kaplan — Mayer multiple assessments 
method with Gehan’s — Wilcoxon criteria has shown 
that survival rates of animals with glioma 101.8 and vac-
cinated animals were significantly different (criteria χ2, 
р = 0.0001). The pairwise comparison of groups using 
Gehan’s — Wilcoxon two-sampling criterion revealed 
the following differences.
Intraperitoneal administration of ATV modified with 
RPNS (0.02 mg/ml) in animals with glioma 101.8 slight-
ly increased the mean survival time (MST) and median 
survival of tumor-bearing rats (MST (16.4 ± 1.9), 
15.5 days compared with MST (14.6 ± 2.8); 14 days; 
p = 0.147) (Table 1, Figure). In contrast, these indices 
in rats with glioma 101.8 after administration of ATV, 
modified with RPNS (0.10 mg/ml), were significantly 
higher than these indices in unvaccinated rats (MST 
(19.9 ± 2.4); 21.4 days compared to MST (14.6 ± 2.8); 
14 days; p = 0.0002), and indices of animals vaccinated 
with ATV, modified with RPNS (0.02 mg/ml) (p = 0.026). 
All animals with glioma 101.8 in untreated group died till 
23th day, while the maximal life span of tumor-bearing 
animals vaccinated with ATV, modified with RPNS 
(0.10 mg/ml) was 25 days.
Comparison of the cytotoxic activity of lymphocytes 
of animals from experimental groups using ANOVA 
by Ranks Kruskal — Wallis test showed highly signifi-
cant differences between them (р = 0.004). The pair-
wise comparison of groups using U-Mann — Whitney 
test revealed the following features.
Table 1. MST and median survival of experimental animals with glioma 
101.8
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1 Rats with glioma 101.8   
(n = 38) 14.6 ± 2.8 14.0 12.0 17.3 −
2 Rats with glioma 
101.8   vaccinated with 
RPNS-modified ATV 
(0.02 mg/ml) (n = 12)
16.4 ± 1.9 15.5 14.0 17.7 р2,1 = 0.147
3 Rats with glioma 
101.8   vaccinated with 
RPNS-modified ATV 
(0.10 mg/ml) (n = 12)
19.9 ± 2.4 21.4 17.8 22.9 р3,1 = 0.0002р3,2 = 0.026
Note: the differences between groups are statistically significant (p < 0.05)
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Figure. Survival curves of experimental animals with glioma 
101.8 (1 — rats with glioma 101.8; 2 — rats with glioma 101.8 vac-
cinated with ATV modified with 0.02 mg/ml RPNS; 3 — rats with 
glioma 101.8 vaccinated with ATV modified with 0.10 mg/ml RPNS)
In intact rats the level of lymphocyte cytotoxic ac-
tivity in MTT-test with glioma 101.8 cells (in allogeneic 
system) was at average 33.2 ± 1.1%.
The cytotoxicity index of lymphocytes from animals 
with glioma 101.8 reached at average 63.1 ± 11.1%, 
exceeding the same indicator of intact animals 
( U-Mann — Whitney test, р = 0.003, Table 2). After ad-
ministration of ATV, modified with RPNS (0.02 mg/ml), 
in rats with glioma 101.8 on the 10th day of tumor trans-
plantation, the cytotoxic activity of immune cells did 
not differ significantly from that index in unvaccinated 
tumor-bearing animals. However, after administration 
of ATV modified with RPNS (0.10 mg/ml), in rats with 
glioma 101.8 cytotoxic activity of lymphocytes was sig-
nificantly increased by an average of 16% ( U-Mann — 
Whitney test, р = 0.026) (see Table 2).
Thus, the i.p. administration of ATV modified with 
RPNS, led to an increase in the ability of immune cells 
to exert cytotoxic effects against allogeneic glioma 
cells in vitro. Administration of ATV, modified with RPNS 
at a concentration of 0.10 mg/ml, proved to be effec-
tive from the standpoint of life span extension.
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Таble 2. Cytotoxic activity of lymphocytes of experimental animals
№ Group
Number 
of ani-
mals, n
Cytotoxic 
index, %
(M ± m)
р (U-
Mann — 
Whitney cri-
terion)
1 Intact rats (control) (n = 12) 6 33.2 ± 1.1 −
2 Rats with glioma 101.8 (n = 38) 6 63.1 ± 11.1 р2,1 = 0.003
3 Rats with glioma 
101.8 vaccinated with ATV modified 
with 0.02 mg/ml RPNS (n = 12)
6 68.1 ± 4.9 р3,1 = 0.029р3,2 = 0.825
4 Rats with glioma 
101.8 vaccinated with ATV modified 
with 0.10 mg/ml RPNS (n = 12)
6 79.7 ± 7.5
р4,1 = 0.009
р4,2 = 0.026
р4,3 = 0.114
Note: the differences between groups are statistically significant (p < 0.05).
As it is shown above, in glioma-bearing animals 
cytotoxic function of immune cells is not reduced, 
conversely, CI of lymphocytes in the test with alloge-
neic glioma cells was higher than in intact (healthy) 
rats. But as far as tumor-bearing animals died till 
23th day, it is evident that antitumor immunity in these 
animals is ineffective. This may be due to different 
mechanisms utilized by glioma allowing its escape 
from immune control. In gliomas, especially malignant, 
a partial or complete loss of expression of HLA anti-
gens class I and/or II [6, 7] occurs, as well as down-
regulation of transport molecules LMP2, TAP1 and 
β2-microglobulin [8]. On the other hand, glioblas-
toma cells and microglial cells/macrophages that 
infiltrate the tumor express nonclassical HLA-G and 
HLA-E molecules with immunomodulatory effects [9, 
10]. It is shown that glioma tumor cells produce IL-10, 
which has immunosuppressive effects on the forma-
tion of local immunity by reducing the expression 
of class II MHC (DR) antigens on monocytes; inhibition 
of T-cell proliferation and allocytolytic activity of lym-
phocytes [3]. Reduced expression of class II MHC 
antigens is one of the reasons for the lack of antitumor 
activity of CD4+ T-lymphocytes. For enhancing the 
efficiency of cellular immunotherapy of gliomas the 
tumor cells needs to become more sensitive to cy-
tolysis by alloreactive cytotoxic lymphocytes (CTLs). 
For this purpose the proinflammatory cytokines 
IFN-γ, IL-1β, TNF-αare used, which can increase the 
expression of MHC antigens class I and II in vitro and 
in vivo in cells of gliosarcoma 9L, medulloblastoma, 
malignant glioma, glioma lines RG2, C6, 9L [28, 29]. 
Increased expression of MHC antigens I and II class 
was accompanied by increased animal survival and 
decreased tumor volume, elevated infiltration of the 
tumor by CD4+ and CD8+ T-cells, better recognition 
of allogeneic CTLs in cytotoxic tests.
One can assume that under the influence of RPNS, 
signaling cascades in glioma cells could be triggered 
leading to increased expression of MHC class I antigens 
and components of mechanism of the antigen pro-
cessing, what promote glioma cells recognition by im-
munocompetent cells. In favor of such assumptions, 
the known data evidence that the rat NPC can express 
and produce a variety of different cytokines, in particular 
IL-1α, IL-1β, IL-6, IL-10, TGF-β1, TGF-β2, TNF-α [30, 
31], LIF [32]. It is likely that IL-1β and TNF-αmay be pre-
sent in RPNS, and can increase the expression of MHC 
antigens І and ІІ class by glioma cells.
It should be mentioned that we have used a modi-
fied MTT-test that allows to determine the total cyto-
toxic activity of effector immune cells — CTLs as well 
as natural killer (NK) cells. It can be assumed that the 
use of RPNS-modified ATV increases the efficiency 
of recognition of allogeneic tumor cells through a more 
effective presentation of antigens and, accordingly, 
leads to increased cytotoxic activity of immune cells. 
Since these immune cells (CTLs and NK-cells) play 
a key role in providing of antitumor immunity, we can 
assume that i.p. administration of RPNS-modified ATV 
induces a more effective immune response against 
glioma 101.8 cells, allowing to extend the life span 
of tumor-bearing animals.
Tumor-suppressive effect in vivo after i.p. admini-
stration of RPNS-modified ATV is obviously caused 
by the increase of efficiency of cytotoxic functions 
of immune cells. This observation could create the ba-
sis for further optimization of whole cell tumor vaccine. 
It is believed that the future of immunotherapy of glio-
mas is a combination of active vaccination and inhibition 
of immunological checkpoints [4]. It is possible that the 
method of modification of ATV using RPNS may be ef-
fective in the clinical development of individualized, 
specific for a particular patient targeted therapy based 
on individual molecular profile of glioma.
CONCLUSION
Intraperitoneal administration of RPNS-modified 
ATV in animals with glioma 101.8 increased MST and 
median survival of glioma 101.8 bearing rats presu mably 
via elevation of cytotoxic activity of immune cells.
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